Lorenzo Falchi

Subcutaneous Epcoritamab Combined With Rituximab + Lenalidomide for the Treatment of Patients with Relapsed or Refractory Follicular Lymphoma: Phase 1/2 Trial Update

Introduction:

Jacob H. Christensen ;

Sven de Vos , MD, PhD;

Kim M. Linton ;

Brian Elliott ;

Sirpa Leppä, ;

Lorenzo Falchi ;

Bjorn E. Wahlin ;

Marcel Nijland ;

11/04/2022

Subcutaneous Epcoritamab Combined With R-CHOP for First-Line Treatment of Patients With High-Risk Diffuse Large B-Cell Lymphoma: Phase 1/2 Update

Introduction:

Lorenzo Falchi ;

Kim M. Linton ;

Brian Elliott ;

Yasmin Karimi ;

Sylvia Snauwaert ;

Michael Roost Clausen ;

11/04/2022

Lorenzo Falchi, MD

Conference Coverage

Subcutaneous Mosunetuzumab Demonstrates Encouraging Efficacy, Manageable Safety as Frontline Therapy for High-Tumor Burden Follicular Lymphoma

01/12/2024

Lorenzo Falchi ;

At the 65th ASH Annual Meeting, Lorenzo Falchi, MD, shares results which indicated that subcutaneous mosunetuzumab as first-line therapy demonstrated efficacious outcomes and manageable safety among patients with high-tumor burden FL.

At the 65th ASH Annual Meeting, Lorenzo Falchi, MD, shares results which indicated that subcutaneous mosunetuzumab as first-line therapy demonstrated efficacious outcomes and manageable safety among patients with high-tumor burden FL.

At the 65th ASH Annual Meeting,...

01/12/2024

Oncology

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Upcoming Events

February 2 ⁠–⁠ February 5

February 27 ⁠–⁠ March 1

DCLF

March 17 ⁠–⁠ March 19

NP Institute

March 27 ⁠–⁠ March 30

March 31 ⁠–⁠ April 2

April 21 ⁠–⁠ April 24

April 30 ⁠–⁠ May 5

April 30 ⁠–⁠ May 4

WoundCon

May 1 ⁠–⁠ May 3

May 19 ⁠–⁠ May 21

See Full Calendar